Search 

Diurnal is an innovative UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

Since our inception in 2004, our company mission has been clear: to address crucial unmet patient and clinical need in the endocrine field and deliver best health outcomes to improve patients’ quality of life.

Diurnal has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

We are an Oxford-based company with a unique and powerful computer-based drug discovery platform and a specialised approach to network biology.  

Our novel methodology and our Discovery Engine allow us to discover new and better drugs in a more efficient and effective way.

Evgen Pharma is a clinical stage drug development company focused on cancer and neurological disease. Our pipeline is based on our proprietary Sulforadex® technology, and includes a number of synthetic, stabilised analogues of the naturally occurring compound sulforaphane. Many peer-reviewed scientific papers have identified the medical potential of sulforaphane in multiple indications. Our objective is to use our Sulforadex® technology to turn this scientific promise into commercially successful products, addressing important clinical needs.

Since 2001, Fusion Antibodies has been dedicated to the discovery and early development of antibodies to help bring about a positive change in the healthcare industry.
We offer a complete range of antibody-related services in Discovery, Engineering and Supply and have guided hundreds of projects through critical preclinical stages.
Fifteen of our client’s projects have advanced to clinical stages, some as far as Phase II.

We deliver a superior service for the development of antibodies by beginning each project with the end in mind. Our scientists are experts in early stage discovery of biologics.

We offer this personalised service because we know that investment at the early stages saves not only millions of dollars but also months, even years of time, on projects that go awry at later stages of development.

Through our vast experience we have developed a number of our own proprietary platforms for Antibody Humanization (CRX™), Affinity Maturation (RAMP™) and Developability optimisation (ADD™).

Fusion Antibodies is a publicly held company, trading on the London Stock Exchange (LSE FAB.L) with headquarters in Belfast, Northern Ireland.

George Medicines is a late-stage drug development company focused on improving the management of non-communicable diseases with innovative, single-pill, fixed-dose combinations of existing medicines.

Combining best-in-class molecules from existing medicines in fixed- and low-dose formulations, George Medicines is developing innovative and proprietary treatments that are more efficacious, safer and affordable than currently available treatment options. These single-pill, fixed-dose combinations offer the potential to bring significant improvements in clinical outcomes and therapy adherence in patients with cardiometabolic diseases such as heart disease, hypertension, and diabetes, which remain the leading causes of premature death and disability worldwide.

George Medicines is building a strong and diversified pipeline of patented, single-pill, fixed-dose combination therapies in late stage development. Its lead candidate for the initial treatment of high blood pressure, GMRx2, has received clearance from the US Food and Drug Administration (FDA) to enter Phase III development.

George Medicines is a venture-backed spin-out company from The George Institute for Global Health, one of the world’s leading medical research institutes in non-communicable diseases.

HC Pharma Consultancy Ltd

Supporting Biotech and Mid-sized Pharma Companies

 

"I can help you build value when partnering or developing your technology"

Isogenica develops LlamdA® VHH: highly versatile small format antibodies which we use to construct next generation biotherapeutics for the treatment of cancer, inflammation and other serious diseases.

LlamdA® VHH can be assembled to create bispecific and multi-specific biotherapeutics, or used to achieve targeted drug delivery as components of ADCs and cell and gene therapies including CAR-Ts.

Isogenica’s partnerships with global biopharmaceutical companies have resulted in a deep pipeline including two clinical Phase assets and partnered pre-clinical and discovery programs.

Register for our upcoming webinar here: https://www.workcast.com/register?cpak=4194507468008465

Oncology specialised clinical development company providing flexible, customised regulatory strategy and clinical development planning, and clinical trial design and execution services to biotechs.

Our clinical development plans have been instrumental in securing funding for many companies.

Headquartered  in Scotland, with offices in Amsterdam and Delaware, and a virtual team in 20+ countries, we execute clinical trials globally. Although specialised in oncology, we also have experience in many other therapeutic areas.

Locust Walk is a global investment bank that integrates the best of strategy consulting with strategic transactions and capital raising for innovative life science companies.  We support management and board members through all aspects of a deal – from clearly defining and assessing all options to developing company positioning and navigating through the full deal cycle from outreach to term sheet structuring to negotiating to close. Our suite of capabilities and data driven approach provides our clients with greater confidence on decision making, faster execution, and less friction working with a single team throughout the process. For more information or to contact a deal team member, please visit https://www.locustwalk.com.

LSX is a growing influential community of senior life science decision makers. We are a catalyst for dialogue, debate and deal making to help lead growth in healthcare investment and the building of billion pound healthcare businesses. We are determined to forge a fundamentally better way to promote and facilitate investment, financing, partnerships and deal making in healthcare.

Our community helps catalyse early stage innovation through peer-to-peer education and knowledge sharing, networking, partnering and deal making to champion the most innovative and exciting ideas. We bring deals to life.